7 completed, 1 active not recruiting, 1 withdrawn. 7 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow BYM338: new trials by email Literature Review of BYM338 trials Research Report on BYM338
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants Bimagrumab, Tirzepatide, Bimagrumab + Tirzepatide Coformulation - Healthy | Phase 1 | Completed | Eli Lilly and Company | 125 | 2025-03-25 | 2025-10-09 |
| A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight Bimagrumab, Tirzepatide, Bimagrumab Placebo - Obesity, Overweight | Phase 2 | Active not recruiting | Eli Lilly and Company | 252 | 2024-10-21 | 2026-05-26 |
| An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 Bimagrumab, Placebo - Sporadic Inclusion Body Myositis | Phase 3 | Completed | Novartis Pharmaceuticals | 211 | 2015-11-02 | 2018-03-13 |
| Dose Range Finding Study of Bimagrumab in Sarcopenia bimagrumab, placebo - Sarcopenia | Phase 2 | Completed | Novartis Pharmaceuticals | 217 | 2014-12-09 | 2021-01-05 |
| Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery bimagrumab, placebo - Muscle Wasting (Atrophy) After Hip Fracture Surgery | Phase 2 | Completed | Novartis Pharmaceuticals | 251 | 2014-09-16 | 2020-08-19 |
| Study of Muscle Effects of BYM338 in Mechanically Ventilated Patients BYM338, Placebo - Mechanical Ventilation | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2014-04-01 | 2015-01-07 | |
| BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia Placebo, BYM338 - Chronic Obstructive Pulmonary Disease (COPD) With Cachexia | Phase 2 | Completed | Novartis Pharmaceuticals | 67 | 2012-09-01 | 2016-05-03 |
| A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults BYM338, Placebo - Skeletal Muscle | Phase 2 | Completed | Novartis Pharmaceuticals | 40 | 2012-01-01 | 2020-12-17 |
| Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis BYM338, Placebo - Sporadic Inclusion Body Myositis | Phase 2 | Completed | Novartis Pharmaceuticals | 14 | 2011-08-01 | 2020-12-17 |
Muscular Atrophy (4) · Cachexia (2) · Myositis, Inclusion Body (2) · Atrophy (1) · Hip Fractures (1) · Obesity (1) · Overweight (1) · Platelet Glycoprotein IV Deficiency (1) · Pulmonary Disease, Chronic Obstructive (1) · Respiratory Insufficiency (1) · Sarcopenia (1)
Novartis Pharmaceuticals (7) · Eli Lilly and Company (2)
United States (8) · Australia (3) · Belgium (3) · France (3) · Japan (3) · Switzerland (3) · United Kingdom (3) · Czechia (2) · Denmark (2) · Germany (2) · Netherlands (2) · Russia (2) · Spain (2) · Taiwan (2) · Argentina (1)
PMID 25381300, PMID 30095981, PMID 33074327, PMID 33597289, PMID 36098133
2015 (1)